Business clinical trial results

NicOx NCX 470 Phase 3 Data Positive

Analysis based on 7 articles · First reported Feb 10, 2026 · Last updated Feb 24, 2026

Sentiment

Attention

Articles

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard

Market Impact

The positive Phase 3 data for NCX 470 is expected to have a significant positive impact on NicOx, potentially leading to a New Drug Application in major markets. This could also benefit its licensees, Ocumension Therapeutics and Kowa (company), by expanding their product portfolios in the ophthalmology sector.

Pharmaceuticals Biotechnology Healthcare

Event Summary

NicOx announced positive Phase 3 clinical trial data for its lead drug candidate, NCX 470, at the 2026 American Glaucoma Society Annual Meeting. NCX 470, a novel nitric oxide-donating bimatoprost eye drop, demonstrated best-in-class intraocular pressure lowering efficacy of up to 10mmHg, meeting the requirements for a New Drug Application in the U.S. and China. The DENALI trial showed NCX 470's non-inferiority and statistical superiority to latanoprost at several time points, with a favorable safety profile. Further presentations highlighted its dual mechanism of action in lowering intraocular pressure. This development is crucial for NicOx and its partners, Ocumension Therapeutics and Kowa (company), as it addresses the unmet need for effective glaucoma treatments.

Key Actions

100 NicOx announced positive Phase 3 data for NCX 470

Entities Involved

stock

NicOx

NicOx announced positive Phase 3 data for its drug candidate NCX 470, which is expected to significantly lower intraocular pressure in glaucoma patients. This positive data validates their development program and could lead to a New Drug Application in the U.S. and China, potentially boosting the company's market position and stock value.

Importance 100 Sentiment 70

stock

Ocumension Therapeutics

Ocumension Therapeutics holds the license for NCX 470 in the Chinese, Korean, and Southeast Asian markets. The positive Phase 3 data for NCX 470 is beneficial for Ocumension Therapeutics as it moves closer to a New Drug Application in these regions.

Importance 40 Sentiment 20

priv

Kowa (company)

Kowa (company) holds the license for NCX 470 in the rest of the world outside of Ocumension Therapeutics' territories. The positive Phase 3 data for NCX 470 is beneficial for Kowa (company) as it moves closer to potential market entry.

Importance 40 Sentiment 20

ngo

American Glaucoma Society

The American Glaucoma Society Annual Meeting served as the platform for NicOx to present its positive NCX 470 Phase 3 data, validating the importance of the drug's development program within the scientific community.

Importance 30 Sentiment 0

per

Doug Hubatsch

Doug Hubatsch, Chief Scientific Officer of NicOx, commented on the importance of the NCX 470 Phase 3 data presentation, emphasizing the need for new treatment options for glaucoma patients.

Importance 20 Sentiment 0

priv

Duke University Hospital

Dr. S. Asrani from Duke University Hospital presented data from the DENALI Trial, a Phase 3 clinical trial for NCX 470, at the American Glaucoma Society Annual Meeting.

Importance 10 Sentiment 0

priv

Mayo Clinic

Dr. A. Sit from Mayo Clinic presented findings on the aqueous humor dynamics of NCX 470 Ophthalmic Solution at the American Glaucoma Society Annual Meeting.

Importance 10 Sentiment 0

+ 4 more entities View on Dashboard

Relationships

NicOx related ↔ Glaukos Corporation

Bausch & Lomb related ↔ NicOx

Harrow related ↔ NicOx

Doug Hubatsch related ↔ NicOx

NEWSDESK

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard